What is the Market Value of Pharmacogenomics Market?

1. Pharmacogenomics Market Revenue To Attain $10,505.3 Million by 2030 1 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

2. In 2021, the global pharmacogenomics market was worth $5,527.2 million, which is set to reach $10,505.3 million, rising at a CAGR of 7.4% from 2021 to 2030. The growing use of pharmacogenomics in the development and discovery of medicines, increasing rate of adverse drug reactions (ADRs), shift from reactive to preventive care, and growing prevalence of cancers and infectious diseases are the key drivers for market growth. Therefore, key players are extensively involved in seeking approvals and product launches to remain competitive. They include Thermo Fisher Scientific Inc., Hoffmann-La Roche Ltd., Myriad Genetics Inc., Abbott Laboratories, Admera Health LLC, QIAGEN N.V., Laboratory Corporation of America Holdings, 23andMe Inc., Exact Sciences Corporation, and Mesa Laboratories Inc. Get the sample pages of this report at: https://www.psmarketresearch.com/market- analysis/pharmacogenomics-market/report-sample Key Findings of Pharmacogenomics Market Report • The sequencing category is expected to experience the highest CAGR due to the growing emphasis on sequencing analysis for various genetic patterns. Furthermore, sequencing approaches have had a significant influence on healthcare by revolutionizing treatment techniques, as genetic information has become more prominent in diagnosis. • Genotyping services hold the largest share in the pharmacogenomics market due to the acquisition of individual genomics profiles by health providers, to offer better services. • Moreover, the United States Clinical Laboratory Improvement Amendments (CLIA) and FDA have been at the forefront of developing effective and acceptable recommendations and regulations, to encourage end users to employ pharmacogenomic tests. • Thus, North America dominated the global pharmacogenomics market in 2021, and it is expected to maintain its dominance in the next years. The government's attempts to incorporate targeted medicine techniques into the mainstream healthcare sector are driving the use of pharmacogenomic procedures in the region. • A key solution provider, Foundation Medicine Inc. gained the FDA clearance for its FoundationOne CDx in December 2021, which will be used as a companion diagnostic (CDx) for two sets of future and existing FDA-approved melanoma treatments. • Similarly, Thermo Fisher Scientific Inc. released the latest version of 2 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

3. SeqStudio Flex Series Genetic Analyzer in March 2022, allowing researchers to conduct research on infectious disease diagnostics and gene editing. The SeqStudio Flex Series Genetic Analyzer features a more-efficient workflow, improved accuracy, and multiple applications. Diagnostic facilities are expected to grow at the highest pharmacogenomics market CAGR in the coming years. Diagnostic centers account for the majority of these items in use, owing to the considerable research, which has resulted in highly complex tests and systems. Furthermore, technological improvements have transformed the services offered by diagnostic centers, thus resulting in higher patient traffic. Direct-to-consumer (DTC) tests are in vitro diagnostic (IVD) tests that are sold directly to consumers without the involvement of healthcare practitioners. The user is often asked to take a specimen (saliva, urine, or other) and send it straight to the corporation for analysis and testing. The number of people who may now obtain genetic information on themselves is growing because of DTC testing, which offers opportunities to market players. The research offers market size of the global pharmacogenomics market for the period 2017– 2030. Market Segmentation by Service Genotyping SNP Identification Pharmacogenetic Testing Other Services Market Segmentation by Technology Polymerase Chain Reaction (PCR) Microarray Sequencing Others Market Segmentation by Application Oncology Infectious Diseases Neurology Cardiovascular Diseases Others Market Segmentation by End User Research Organizations • • • • • • • • • • • • • • oBy service 3 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

4. Pharmaceutical Companies • oBy service Diagnostic Centers • oBy service Others • oBy service Market Segmentation by Region North America Pharmacogenomics Market • oBy service oBy technology oBy application oBy end user oBy country – U.S. and Canada Europe Pharmacogenomics Market • oBy service oBy technology oBy application oBy end user oBy country – Germany, France, U.K., Italy, Spain and Rest of Europe Asia-Pacific (APAC) Pharmacogenomics Market • oBy service oBy technology oBy application oBy end user oBy country – China, India, Japan and Rest of APAC Latin America (LATAM) Pharmacogenomics Market • oBy service oBy technology oBy application oBy end user oBy country – Brazil, Mexico, and Rest of LATAM Middle East and Africa (MEA) Pharmacogenomics Market • oBy service oBy technology oBy application oBy end user 4 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

5. oBy country – Saudi Arabia, South Africa, and Rest of MEA 5 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved

6. Disclaimer: P&S Intelligence always keeps its customers’ interests at the core while carrying out research activities. P&S Intelligence ensures the reliability and accuracy of information and data provided in its market research publications. However, the information in publications is subject to fluctuations, as it is based on primary interviews of officials from various companies or organizations. P&S Intelligence is not responsible for any incorrect data provided by the key industry players of the concerned domain. The information or analysis in P&S Intelligence publications represents opinions based on research and should not be interpreted as statements of fact. Information in this report was believed to be correct at the time of publication, but cannot be guaranteed. P&S Intelligence does not endorse any product, service, or vendor depicted in its research publications. All intellectual properties, including trademarks and copyrights, belong to their respective owners and may be protected by copyright. Under no circumstance can these be reproduced in any form without prior written agreement of their owners. An order for market research report is intended for internal use of the company only and not for disclosure to third parties or any other publication in general. No service, report, or part thereof provided by P&S Intelligence can be reproduced, republished, resold, revealed, distributed, circulated, or sublicensed in any medium or form now realized or hereafter become realized, including but not limited to, all forms of optical-based media, magnetic, electronic, or digital, without a written permission from Prescient & Strategic Intelligence Pvt. Ltd. Kindly write to: enquiry@psmarketresearch.com B-13, Sector – 2, Noida, U.P. – 201301, INDIA Contact No: +91 120 4541 337 US/Canada Toll-Free: 1-888-778-7886 6 © Prescient & Strategic (P&S) Intelligence Pvt. Ltd. All rights reserved